Contributed equally to this artice: JZ and JM-B, SE and ED.
Identification of HLA class I dependent immunogenic peptides from clonotypic TCRβ expressed in cutaneous T-cell lymphoma
Article first published online: 20 JUL 2006
Copyright © 2006 Wiley-Liss, Inc.
International Journal of Cancer
Volume 119, Issue 10, pages 2476–2480, 15 November 2006
How to Cite
Zeng, J., Müller-Berghaus, J., Nguyen, X. D., Klüter, H., Schönhaber, H., Song, M., Schwinn, N., Schadendorf, D., Goerdt, S., Eichmüller, S. and Dippel, E. (2006), Identification of HLA class I dependent immunogenic peptides from clonotypic TCRβ expressed in cutaneous T-cell lymphoma. Int. J. Cancer, 119: 2476–2480. doi: 10.1002/ijc.22113
- Issue published online: 26 SEP 2006
- Article first published online: 20 JUL 2006
- Manuscript Accepted: 27 APR 2006
- Manuscript Received: 28 NOV 2005
- Deutsche Forschungsgemeinschaft. Grant Number: Ei433/1-5
- Tumorzentrum Heidelberg/Mannheim
- cutaneous T-cell lymphoma;
- reverse immunology;
- T cells
The clonotypic T-cell receptor (TCR) is a potential target antigen for specific immunotherapy of cutaneous T-cell lymphoma (CTCL). We identified T-cell epitopes from the rearranged TCR β chain of the malignant T-cell population by the “reverse immunology” approach. Peptide-specific T-cell lines were generated against predicted epitopes and tested for the recognition of tumor cells and cells transfected with the full-length DNA coding for TCRV β chain. Two peptides derived from the clonotypic TCRVβ of a HLA-A2 positive patient could induce peptide-specific T cells from peripheral blood mononuclear cells of healthy donors and the patient as assessed by IFN-γ ELISpot assay. Furthermore, the reactive CTLs efficiently recognized autologous Sézary tumor cells, as well as HLA-A2 positive 293 cells transfected with recombinant plasmid expressing the corresponding TCRVβ29 protein. Similar results were obtained in a HLA-A3+ patient for TCRVβ7-Jβ2.7. In conclusion, our experiments show that the TCR β chain harbors epitopes suitable as targets for specific vaccination which might be a promising approach for the specific immunotherapy of cutaneous T-cell lymphoma patients. © 2006 Wiley-Liss, Inc.